Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCAP-XX Regulatory News (CPX)

Share Price Information for CAP-XX (CPX)

Share Price is delayed by 15 minutes
Get Live Data
0.265    -0.005 (-1.85%)
Bid:
0.25
Ask:
0.28
Spread: 0.03 (12.00%)
Market Cap: £15.36m
CPX Live PriceLast checked at - London Stock Exchange

Intraday CAP-XX Share Chart

Trading update

20 Jun 2018 07:00

RNS Number : 9258R
CAP-XX Limited
20 June 2018
 

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).

 

20 June 2018

 

CAP-XX Limited

("CAP-XX" or "the Company")

Trading update

 

The Board of CAP-XX is pleased to announce that as it approaches the end of its financial year ending 30 June 2018, the Company has received a sharp increase in enquiry levels across all product ranges, including its recently announced 3 Volt technology. Total enquiries, if converted to orders, would amount to annualised sales in excess of US$20m per annum, including over US$2m which has already been classed as design wins, covering over 70 projects for cylindrical and automotive supercapacitors; small IoT and Thinline supercapacitors; and the new 3 Volt prismatic supercapacitors that are in development.

Following on from the announcement made in April 2018, the Company's new 3 Volt technology programme remains on track. As previously stated, the Board believes that the development of a 3 Volt prismatic supercapacitor will be a breakthrough for IoT applications using coin cell batteries. CAP-XX is currently commencing production trials and holding discussions with potential customers and licencees.

Royalty payments continue to grow strongly. Licensing activity remains a key focus, as CAP-XX negotiates new agreements and tackles intellectual property infringements. The Company expects to announce further progress in these respects shortly.

Revenues for the second half of the financial year ending 30 June 2018 are expected to be A$3.35m, including licence payments from AVX, which are significantly ahead of the first half of the year (first half total revenues: A$1.54m). These revenues are expected to result in a reduced EBITDA loss for the second half of the year of approximately A$120,000, compared to the first half EBITDA loss of A$1.5m.

The second half of the financial year includes revenues from the previously announced high volume order for prismatic cells, which has reduced the Company's average selling price by approximately 20%. This selling price reduction, together with the extra start-up costs for this production (as already reported); relocating manufacturing assets from a former contract manufacturer's site; and pursuing patent infringement actions, has reduced the Company's margins. For the financial year ending 30 June 2018, the Board therefore anticipates CAP-XX will generate total revenues of not less than A$4.9m and an EBITDA loss of A$1.6m. Closing cash is anticipated to be in excess of A$1.8m.

 

For further information contact:

 

CAP-XX Limited

Anthony Kongats (Chief Executive Officer) +61 (0) 2 9428 0139

Kreab (Financial PR)

Robert Speed +44 (0) 20 7074 1800

Allenby Capital (Nominated Adviser and Broker)

David Hart / Alex Brearley (Corporate Finance) +44 (0) 20 3328 5656

 

More information is available at www.cap-xx.com

 

Notes to Editors:

CAP-XX (LSE: CPX) is a world leader in the design and manufacture of thin, flat supercapacitors and energy management systems used in portable and small-scale electronic devices, and large supercapacitor based modules used in larger applications such as automotive and renewable energy. The unique feature of CAP-XX supercapacitors is their very high power density and high energy storage capacity in a space-efficient prismatic package. These attributes are essential in power-hungry consumer and industrial electronics, and deliver similar benefits in automotive and other transportation applications. For more information about CAP-XX, visit www.cap-xx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTGGUBPQUPRPPB
Date   Source Headline
2nd Feb 20267:00 amRNSInterim Results
23rd Jan 20267:00 amRNSNotice of Interim Results & Investor Presentation
19th Dec 202510:13 amRNSReceipt of R&D tax credit
19th Dec 202510:13 amRNSReceipt of R&D tax credit
10th Dec 20252:16 pmRNSHolding(s) in Company
28th Nov 20255:00 pmRNSTotal Voting Rights
28th Nov 202510:13 amRNSResult of AGM
14th Nov 20257:00 amRNSIssue of Shares and Director/PDMR Shareholding
10th Nov 20257:00 amRNSDirector/PDMR Shareholding
7th Nov 20257:00 amRNSFinal results and notice of AGM
30th Oct 20251:02 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSHolding(s) in Company
16th Sep 20257:00 amRNSImplementation of Warehouse Management System
10th Sep 202511:48 amRNSHolding(s) in Company
7th Aug 20257:00 amRNSHolding(s) in Company
5th Aug 20257:00 amRNS-RDesign Win with Global Semiconductor Manufacturer
31st Jul 20255:00 pmRNSTotal Voting Rights
25th Jul 20257:00 amRNSHolding(s) in Company
18th Jul 20257:00 amRNSUpdate re. collaboration with SCHURTER
2nd Jul 20257:00 amRNSHolding(s) in Company
1st Jul 20257:29 amRNSIssue of Shares and Director/PDMR Shareholdings
30th Jun 20257:00 amRNSGlobal Distribution Agreement with RS Group plc
9th Jun 20257:00 amRNSBusiness Update and Appointment of Interim CFO
30th May 202510:32 amRNS-RUpdated website
13th May 202511:31 amRNS-RDesign Win with Multinational Conglomerate
30th Apr 20251:57 pmRNSChange of Auditor
26th Mar 20257:00 amRNSGrant of share options
19th Mar 20257:00 amRNSChange of Board Structure and Grant of Options
18th Mar 20259:35 amRNSGlobal Distribution Agreement with Premier Farnell
12th Mar 20252:43 pmRNSTechnology Cooperation Agreement with SCHURTER
7th Mar 20257:00 amRNSMaster Distribution Agreement with Waldom
17th Feb 20257:00 amRNSHalf-year Results
11th Feb 20257:00 amRNSNotice of Interim Results & Investor Presentation
31st Jan 20255:00 pmRNSTotal Voting Rights
21st Jan 20254:27 pmRNSIssue of Shares and Director/PDMR Shareholding
20th Jan 20257:00 amRNSUpdate re. R&D Tax Credit
20th Jan 20257:00 amRNSUpdate re. R&D Tax Credit
17th Jan 20257:00 amRNS-RDistribution agreement with JM Elektronik
15th Jan 20257:00 amRNSFirst shipment to SCHURTER AG
13th Jan 202511:29 amRNSResult of AGM
7th Jan 20257:00 amRNSManagement and board changes
31st Dec 20241:00 pmRNSTotal Voting Rights
9th Dec 202410:19 amRNSNotice of AGM
5th Dec 20248:18 amRNSResult of General Meeting
29th Nov 20245:00 pmRNSTotal Voting Rights
29th Nov 20249:57 amRNSDirectors' Subscription
29th Nov 20247:00 amRNSAudited results for the year ended 30 June 2024
5th Nov 20247:00 amRNSResult of Retail Offer, Notice of GM and TVR
1st Nov 20247:00 amRNSResult of Placing
31st Oct 20244:40 pmRNSRetailBook Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.